Salud financiera de hoja de balance de PYC Therapeutics

Salud financiera controles de criterios 6/6

PYC Therapeutics tiene un patrimonio de los accionistas total de A$81.1M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$91.2M y A$10.2M respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$66.87m
Patrimonio	AU$81.05m
Total pasivo	AU$10.18m
Activos totales	AU$91.24m

Actualizaciones recientes sobre salud financiera

Recent updates

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Oct 25

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Apr 10

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

Nov 10

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Jul 03

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Jan 25

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Jul 31

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

Mar 28

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$85.6M) de PYC superan a sus pasivos a corto plazo (A$9.1M).

Pasivo a largo plazo: Los activos a corto plazo de PYC (A$85.6M) superan a sus pasivos a largo plazo (A$1.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PYC está libre de deudas.

Reducción de la deuda: PYC no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PYC tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: PYC dispone de suficiente cash runway para 1.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 33.2% cada año.

Salud financiera de hoja de balance de PYC Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Recent updates

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy